Valuation : Xspray Pharma AB

Market Cap 486M 50.65M 43.65M 40.93M 37.36M 70.38M 4.84B 70.6M 189M 2.44B 190M 186M 8.1B P/E 2026 *
-1.65x
P/E 2027 * 3.1x
Enterprise Value 486M 50.65M 43.65M 40.93M 37.36M 70.38M 4.84B 70.6M 189M 2.44B 190M 186M 8.1B EV / Sales 2026 *
25.2x
EV / Sales 2027 * 0.86x
Free-Float
78.32%
Yield 2026 *
-
Yield 2027 * -
1 day-0.68%
1 week-3.82%
Current month-40.40%
1 month-38.13%
3 months-58.17%
6 months-60.32%
Current year-68.01%
1 week 10
Extreme 10
10.8
1 month 10
Extreme 10
17.24
Current year 10
Extreme 10
32.5
1 year 10
Extreme 10
64.1
3 years 10
Extreme 10
91.7
5 years 10
Extreme 10
147.2
10 years 10
Extreme 10
267
Manager TitleAgeSince
Chief Executive Officer - 2026-05-31
Director of Finance/CFO 34 -
Chief Operating Officer 52 2024-05-31
Director TitleAgeSince
Director/Board Member 70 2014-12-31
Director/Board Member 52 2018-12-31
Chairman 72 2022-05-18
Date Insider Type Main position Quantity % Market Cap.
8/20/26 Buy

Director

3,690 0.0078%
6/3/26 Sell

Director

-19,999 0.0422%
6/3/26 Buy

Director

26,620 0.0561%
Change 5-day change 1-year change 3-year change Capi.($)
-1.76%-3.82%-77.52%-68.06% 51.02M
-1.59%-6.25%+64.99%+99.09% 70.64B
-1.34%-0.75%+48.56%+90.63% 66.11B
-7.77%-11.76%+0.91%-14.77% 27.98B
-2.53%-5.72%-12.15%+448.43% 26.51B
+0.30%+2.03%+59.48%+14.21% 26.44B
-0.96%+12.36%+280.38%+439.54% 20.4B
-0.51%+0.23%+33.71%-18.02% 20.17B
-1.91%-3.47%+11.03%+508.52% 15.99B
-2.04%+0.18%+42.96%+144.27% 13.69B
Average -1.89%+0.85%+45.23%+164.38% 28.8B
Weighted average by Cap. -1.95%+1.22%+56.38%+151.23%

Financials

2026 *2027 *
Net sales 19.3M 2.01M 1.74M 1.63M 1.48M 2.8M 192M 2.81M 7.53M 97.14M 7.56M 7.4M 322M 564M 58.84M 50.7M 47.54M 43.4M 81.75M 5.62B 82.01M 220M 2.84B 221M 216M 9.41B
Net income - -
Net Debt - -
Logo Xspray Pharma AB
XSpray Pharma AB (publ), formerly Xspray Microparticles AB, is a Sweden-based biotechnology company. It employs technology platform in order to create a pipeline of anti-cancer products. The Company primarily develops protein kinase inhibitors (PKI) for targeted cancer treatments. The product candidates include Sprycel, also known as HyNap-Dasa, (version of dasatinib medicine), Tasigna, also under name HyNap-Nilo, (version of nilotinib medicine) and Nexavar, also is under name HyNap-Sora, (version of sorafenib medicine), among others. Sprycel and Tasigna are indicated for treatment of adult patients diagnosed with Philadelphia chromosome-positive (pH+) chronic myeloid leukemia (CML). Sprycel is also indicated for the treatment of adult patients with pH+ acute lymphocytic leukemia (ALL) and lymphoid blastic CML with resistance or intolerance to prior treatment. Nexavar is indicated for the treatment of patients with liver cell cancer, renal cell cancer and differentiated thyroid cancer.
Employees
24
Date Price Change Volume
26-08-28 SEK 10.06 -1.76% 125,563
26-08-27 SEK 10.24 -1.92% 77,724
26-08-26 SEK 10.44 -2.79% 78,894
26-08-25 SEK 10.74 +4.88% 97,686
26-08-24 SEK 10.24 -2.10% 195,618

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. XSPRAY Stock